恩科拉非尼联合西妥昔单抗联合或不联合阿培利司治疗转移性BRAF突变结直肠癌的Ib期剂量递增研究
这是一项Ib期剂量递增研究,纳入难治性BRAF V600突变转移性结直肠癌患者,分别接受恩科拉非尼联合西妥昔单抗双药治疗(n=26),或在此基础上加用PI3Kα抑制剂阿培利司的三药治疗(n=28)。主要目标是确定最大耐受剂量(MTD)或II期推荐剂量,双药组与三药组均未达到MTD,两组的II期剂量均选择恩科拉非尼200 mg,三药组的阿培利司剂量为300 mg。
要点
- 双药组与三药组均未达到最大耐受剂量,II期剂量均选择恩科拉非尼200 mg。
- 双药组确认的总体缓解率为19%,三药组为18%。
- 双药组的中位无进展生存期为3.7个月,三药组为4.2个月。
核心结论
- 作者认为,恩科拉非尼联合西妥昔单抗的双药方案,以及在此基础上加用阿培利司的三药方案,在难治性BRAF突变转移性结直肠癌患者中均可耐受,并显示出有前景的临床活性。
研究设计与样本
- Ib期剂量递增研究,纳入难治性BRAF V600突变转移性结直肠癌患者,双药组(恩科拉非尼联合西妥昔单抗)n=26,三药组(再加阿培利司)n=28,主要目标为确定最大耐受剂量或II期推荐剂量。
主要发现
- 双药组有3例、三药组有2例患者报告剂量限制性毒性。
- 双药组与三药组均未达到最大耐受剂量,两组的II期剂量均选择恩科拉非尼200 mg,三药组的阿培利司剂量为300 mg。
- 双药组确认的总体缓解率为19%,三药组为18%。
- 双药组的中位无进展生存期为3.7个月,三药组为4.2个月。
临床怎么用
- 原文未据此给出推荐,仅报告双药与三药联合方案在BRAF突变转移性结直肠癌患者中可耐受并显示有前景的临床活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in BRAFV600E colorectal cancer models. Patients with refractory BRAFV600-mutant metastatic CRC (mCRC) were treated with a selective RAF kinase inhibitor (encorafenib) plus a monoclonal antibody targeting EGFR (cetuximab), with (n = 28) or without (n = 26) a PI3Kα inhibitor (alpelisib). The primary objective was to determine the maximum tolerated dose (MTD) or a recommended phase II dose. Dose-limiting toxicities were reported in 3 patients receiving dual treatment and 2 patients receiving triple treatment. The MTD was not reached for either group and the phase II doses were selected as 200 mg encorafenib (both groups) and 300 mg alpelisib. Combinations of cetuximab and encorafenib showed promising clinical activity and tolerability in patients with BRAF-mutant mCRC; confirmed overall response rates of 19% and 18% were observed and median progression-free survival was 3.7 and 4.2 months for the dual- and triple-therapy groups, respectively.Significance: Herein, we demonstrate that dual- (encorafenib plus cetuximab) and triple- (encorafenib plus cetuximab and alpelisib) combination treatments are tolerable and provide promising clinical activity in the difficult-to-treat patient population with BRAF-mutant mCRC. Cancer Discov; 7(6); 610-9. ©2017 AACR.See related commentary by Sundar et al., p. 558This article is highlighted in the In This Issue feature, p. 539.
引用
- van Geel RMJM, Tabernero J, Elez E, et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. Cancer Discov. 2017. PMID: 28363909. doi:10.1158/2159-8290.CD-16-0795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。